Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)

BPS Bioscience

Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)

7

Neutralisation/Blocking

Research Use Only

The titer will vary with each lot; the exact value is provided with each shipment. The minimal titer is >106 TU/ml.

The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 D614G variant in a Biosafety Level 2 facility. The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based spike pseudoviruses for use in cells such as Vero-E6 parental cells.

-80°C

41116133